Abstract
Previos data of our group show the possibility to engineer immunomodulator VLPs with the capacity to potentialize antitumor imumne response. These VLPs derive from retroviral capsides and are encrusted with anchored proteins in the particle surface. We observed that VLPs containing the CD40 ligand, CD40L, activate presenting cells and potencialize the antitumoral immune reponse in animals…